NCT01958957

A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 6,300 (actual)
• Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.

Detailed description

Ginkgolides Meglumine Injection was jointly developed by China Pharmaceutical University and Jiangsu Kanion Pharmaceutical Co., Ltd. Its pharmacal ingredients are ginkgo lactones , ginkgo lactone B, ginkgo lactone K, etc; Excipients for meglumine, citric acid, sodium chloride. It is used to treat stroke (mild-to-moderate cerebral infarction) in recovery phlegm and Syndrome of Intermingled Phlegm and Blood Stasis. The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Ginkgolides Meglumine Injection	25mg, intravenous drip, once a day. Number of Cycles: 14 days.

Timeline

• Start date: 2013-06-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2013-10-09
• Last updated: 2014-12-24

Locations

86 sites across 1 country: China